Advertisement

Topics

ASCO 2018: Upfront comprehensive genetic testing in advanced lung cancer Is cost-effective

10:48 EDT 17 May 2018 | ecancermedicalscience

An economic model comparing different types of genetic testing in metastatic non-small-cell lung cancer (NSCLC) found that using next-generation sequencing (NGS) to test for all known lung cancer-related gene changes at the time of diagnosis was more...

Original Article: ASCO 2018: Upfront comprehensive genetic testing in advanced lung cancer Is cost-effective

NEXT ARTICLE

More From BioPortfolio on "ASCO 2018: Upfront comprehensive genetic testing in advanced lung cancer Is cost-effective"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...